Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Darusentan (Lu-135252) 是内皮素受体 A (ET-A) 受体选择性拮抗剂,能够作用于 ET-A 受体(Ki:1.4 nM)及ET-B 受体(Ki:184 nM),对 ETA 受体的选择性大于 ETB 受体的100以上。它在大鼠主动脉血管平滑肌细胞膜中竞争结合放射性标记的内皮素(Ki:13 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 397 | 现货 | ||
2 mg | ¥ 595 | 现货 | ||
5 mg | ¥ 996 | 现货 | ||
10 mg | ¥ 1,830 | 现货 | ||
25 mg | ¥ 3,120 | 现货 | ||
50 mg | ¥ 4,590 | 现货 | ||
100 mg | ¥ 6,530 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 997 | 现货 |
产品描述 | Darusentan (Lu-135252) is a potent inhibitor of endothelin signaling and function in both large and small arteries |
体外活性 | Darusentan inhibits endothelin-induced signaling related to pro-contractile activity and is a potent inhibitor of vasoconstriction in large and small arteries. |
细胞实验 | Briefly, isolated rat aortic smooth muscle cells were incubated overnight in complete media in a 96-well microplate at a density of 50 000 cells/well. The next day, cells were starved for 24 h in 0% serum conditions. Following starvation, medium was removed and cells were dosed with 20 μL of increasing concentrations of darusentan (0, 0.001, 0.01, 0.1, 1, and 10 μmol/L) made in stimulation buffer containing 50 mmol/L LiCl. Cells were incubated at 37 °C, 5% CO2 for 30 min before the addition of 20 μL of ET-1 in dose-response fashion. Cells were incubated in the presence or absence of darusentan and ET-1 at 37 °C, 5% CO2 for 60 min. Following this incubation, cells were lysed using 20 μL of 2.5% lysis solution for 30 min and lysates were transferred to a 96-well microplate pre-coated with goat anti-mouse IgG. After transfer into the ELISA plate, kit-supplied IP1-horseradish peroxidase (HRP) conjugate and anti-IP1 mAb were added to the lysates. Assays were incubated for 3 h at room temperature on a platform shaker. Assay plates were then washed 6 times with 1× ELISA wash solution (250 μL/well) before the addition of HRP substrate TMB (3, 3', 5, 5'-tetramethylbenzidine). After 20 min, the reaction was stopped and the optical density (OD) was measured at 450 nm with a correction of 620 nm. Measurements were performed in triplicate. |
别名 | Lu-135252, 达卢生坦 |
分子量 | 410.43 |
分子式 | C22H22N2O6 |
CAS No. | 171714-84-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (304.57 mM)
H2O: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4365 mL | 12.1823 mL | 24.3647 mL | 60.9117 mL |
5 mM | 0.4873 mL | 2.4365 mL | 4.8729 mL | 12.1823 mL | |
10 mM | 0.2436 mL | 1.2182 mL | 2.4365 mL | 6.0912 mL | |
20 mM | 0.1218 mL | 0.6091 mL | 1.2182 mL | 3.0456 mL | |
50 mM | 0.0487 mL | 0.2436 mL | 0.4873 mL | 1.2182 mL | |
100 mM | 0.0244 mL | 0.1218 mL | 0.2436 mL | 0.6091 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Darusentan 171714-84-4 GPCR/G Protein Endothelin Receptor vascular ET-A Lu-135252 rat muscle Inhibitor Lu 135252 receptor aortic endothelin inhibit smooth RAVSMs Lu135252 达卢生坦 inhibitor